ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

Zacks Education
Visit Zacks' Education section for investing guides and other free resources to make you a better investor.

Quote:

Search for Ticker

Free Membership

Search:

QGEN: Qiagen Nv Ord - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

QIAGEN NV ORD (NASD)
QGEN	21.36	-0.28	(-1.29%)	Vol. 1,718,327	16:00 ET

Qiagen NV produces biomedical and genetic products, products for separating and purifying nucleic acids for gene-based drug screening, nucleic acid-based clinical diagnostics, genetic vaccination and gene therapy.

General Information

QIAGEN NV

Spoorstraat 50 5911 KJ Venlo, - - Phone: 011-31-77-320-8400 Fax: 49-2103-29-21710 Web: www.qiagen.com Email: IR@qiagen.com

Industry	MED-BIOMED/GENE
Sector:	Medical

Fiscal Year End	December
Last Reported Quarter	09/30/09
Next EPS Date	02/08/2010

Price and Volume Information

Zacks Rank
Yesterday's Close	21.64
52 Week High	23.58
52 Week Low	14.32
Beta	0.77
20 Day Moving Average	1,021,935.31
Target Price Consensus	21.59

% Price Change
4 Week	-0.42
12 Week	4.82
YTD	22.49

% Price Change Relative to S&P 500
4 Week	-1.49
12 Week	-1.17
YTD	1.38

Share Information
Shares Outstanding (millions)	199.07
Market Capitalization (millions)	4,282.08
Short Ratio	4.62
Last Split Date	07/14/2000

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	0.24
Current Year EPS Consensus Estimate	0.90
Estimated Long-Term EPS Growth Rate	23.80
Next EPS Report Date	02/08/2010

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	1.73
30 Days Ago	1.73
60 Days Ago	1.91
90 Days Ago	1.91

Fundamental Ratios

P/E
Current FY Estimate:	23.83
Trailing 12 Months:	24.44
PEG Ratio	1.00

EPS Growth
vs. Previous Year	19.05%
vs. Previous Quarter	8.70%

Sales Growth
vs. Previous Year	12.50%
vs. Previous Quarter:	8.12%

Price Ratios
Price/Book	1.92
Price/Cash Flow	15.68
Price / Sales	4.47

ROE
09/30/09	10.74
06/30/09	11.50
03/31/09	11.23

ROA
09/30/09	5.76
06/30/09	5.88
03/31/09	5.74

Current Ratio
09/30/09	3.65
06/30/09	2.97
03/31/09	3.17

Quick Ratio
09/30/09	3.29
06/30/09	2.52
03/31/09	2.67

Operating Margin
09/30/09	18.72
06/30/09	18.29
03/31/09	18.13

Net Margin
09/30/09	16.61
06/30/09	14.81
03/31/09	13.69

Pre-Tax Margin
09/30/09	16.61
06/30/09	14.81
03/31/09	13.69

Book Value
09/30/09	11.19
06/30/09	7.74
03/31/09	7.39

Inventory Turnover
09/30/09	2.72
06/30/09	2.76
03/31/09	2.74

Debt-to-Equity
09/30/09	0.40
06/30/09	0.62
03/31/09	0.65

Debt to Capital
09/30/09	28.74
06/30/09	38.20
03/31/09	39.34


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research